NCT05903092 2026-03-12
MOZART
Hoosier Cancer Research Network
Phase 2 Suspended
Clinical Trials
10 trialsNCT06385262 2026-03-06
TOP 2301: Neoadjuvant Chemo for NSCLC
Duke University
Phase 2 Suspended
NCT05960773 2026-03-04
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 2 Suspended
NCT05337735 2025-10-09
A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
M.D. Anderson Cancer Center
Phase 2 Suspended
NCT02356991 2019-11-04
A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Suspended
NCT01723306 2016-06-14
Phase II/Pilot Study of 2nd Generation Anti-CEA Designer T Cells in Adenocarcinomas
Roger Williams Medical Center
Phase 2 Suspended
NCT01356303 2016-05-13
TAXIS01
National Guard Health Affairs
Phase 2 Suspended
NCT02470065 2016-01-22
REMNANT
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Suspended
NCT00986284 2015-12-22
Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Suspended
NCT01088620 2013-03-14
Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung Cancer
WiSP Wissenschaftlicher Service Pharma GmbH
Phase 2 Suspended